Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Jun 2008 Actual study completion date August 2005 added as reported by ClinicalTrials.gov
- 09 Jun 2008 The primary endpoint is total nasal symptom score as reported by ClinicalTrials.gov
- 09 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov